Clinical Research Management announced it has been awarded a new, 5-year, $97MM research support contract titled Support for Military Medical Research for the Soldier (SMMRS) to be performed at the Walter Reed Army Institute of Research (WRAIR). The United States Army Medical Research Acquisition Activity (USAMRAA) awarded the contract to ClinicalRM. USAMRAA is both the contracting element of the US Army Medical Research and Materiel Command (USAMRMC) and the provider of support to the Command headquarters and its worldwide network of laboratories and medical logistics organizations.
Through the course of the contract, ClincalRM will provide support for WRAIR’s goal of improving both national and international efforts to develop drugs, vaccines and associated products to address diseases of strategic interest to the United States Military and to develop products to enhance warfighter resilience, and reduce and mitigate the impact of brain injury and combat stress.
“We are very proud of the support our company currently provides to WRAIR which makes this award especially important. It is a testament to the value we bring to critical research that supports the warfighter and our country,” said Victoria Tifft, founder and CEO of ClinicalRM.
For 18 years, ClinicalRM has proven itself as a trusted partner to the US Armed Forces providing basic and applied research, clinical trials, and regulatory approval for a wide variety of agents. The SMMRS contract start date is July 1, 2011.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.